Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) FCF Margin (2024 - 2025)

Historic FCF Margin for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to 91.76%.

  • Xilio Therapeutics' FCF Margin rose 5127900.0% to 91.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 55.28%, marking a year-over-year change of. This contributed to the annual value of 290.26% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Xilio Therapeutics' FCF Margin is 91.76%, which was up 5127900.0% from 180.7% recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' FCF Margin ranged from a high of 979.04% in Q1 2025 and a low of 821.52% during Q4 2024